|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raoul JL, Kudo M, Finn RS, Edeline J, Reig
M and Galle PR: Systemic therapy for intermediate and advanced
hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev.
68:16–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grothey A, Blay JY, Pavlakis N, Yoshino T
and Bruix J: Evolving role of regorafenib for the treatment of
advanced cancers. Cancer Treat Rev. 86:1019932020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Korita PV, Wakai T, Shirai Y, Matsuda Y,
Sakata J, Takamura M, Yano M, Sanpei A, Aoyagi Y, Hatakeyama K and
Ajioka Y: Multidrug resistance-associated protein 2 determines the
efficacy of cisplatin in patients with hepatocellular carcinoma.
Oncol Rep. 23:965–972. 2010.PubMed/NCBI
|
|
6
|
Plimack ER, Dunbrack RL, Brennan TA,
Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi
E, Palma N, et al: Defects in DNA repair genes predict response to
neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder
cancer. Eur Urol. 68:959–967. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zamble DB and Lippard SJ: Cisplatin and
DNA repair in cancer chemotherapy. Trends Biochem Sci. 20:435–439.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu AX: Systemic therapy of advanced
hepatocellular carcinoma: How hopeful should we be? Oncologist.
11:790–800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Camargo FD, Gokhale S, Johnnidis JB, Fu D,
Bell GW, Jaenisch R and Brummelkamp TR: YAP1 increases organ size
and expands undifferentiated progenitor cells. Curr Biol.
17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guan KLL: Regulation and function of the
Hippo-YAP pathway in organ size, tumorigenesis, and metastasis.
Cancer Res. 72 (Suppl 8):SY29–03. 2012.PubMed/NCBI
|
|
12
|
Yu FX, Zhao B and Guan KL: Hippo pathway
in organ size control, tissue homeostasis, and cancer. Cell.
163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao B, Li L, Lei Q and Guan KL: The
Hippo-YAP pathway in organ size control and tumorigenesis: An
updated version. Genes Dev. 24:862–874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Yue T and Jiang J: Hippo
signaling pathway and organ size control. Fly (Austin). 3:68–73.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Y, Li D, Li H, Wang L, Tian G and
Dong Y: YAP overexpression promotes the epithelial-mesenchymal
transition and chemoresistance in pancreatic cancer cells. Mol Med
Rep. 13:237–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Corvaisier M, Bauzone M, Corfiotti F,
Renaud F, El Amrani M, Monté D, Truant S, Leteurtre E, Formstecher
P, Van Seuningen I, et al: Regulation of cellular quiescence by
YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in
chemoresistance and cancer relapse. Oncotarget. 7:56699–56712.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qin J, Luo M, Qian H and Chen W:
Upregulated miR-182 increases drug resistance in cisplatin-treated
HCC cell by regulating TP53INP1. Gene. 538:342–347. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F
and Xia Q: Cisplatin-induced downregulation of miR-199a-5p
increases drug resistance by activating autophagy in HCC cell.
Biochem Biophys Res Commun. 423:826–831. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng T, Wang J, Jiang H and Liu L: Hippo
signaling in oval cells and hepatocarcinogenesis. Cancer Lett.
302:91–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu-Chittenden Y, Huang B, Shim JS, Chen
Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological
disruption of the TEAD-YAP complex suppresses the oncogenic
activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Uddin A and Chakraborty S: Role of miRNAs
in lung cancer. J Cell Physiol. Apr 20–2018.(Online ahead of
print). View Article : Google Scholar
|
|
23
|
Liu AM, Poon RT and Luk JM: MicroRNA-375
targets Hippo-signaling effector YAP in liver cancer and inhibits
tumor properties. Biochem Biophys Res Commun. 394:623–627. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Cui M, Sun BD, Liu FB, Zhang XD
and Ye LH: MiR-506 suppresses proliferation of hepatoma cells
through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 35:1207–1214.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long
HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation
of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct.
33:326–333. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan G, Cao X, Dai Q, Zhang B, Huang J,
Xiong S, Zhang YY, Chen W, Yang J and Li H: A novel role for
microRNA-129-5p in inhibiting ovarian cancer cell proliferation and
survival via direct suppression of transcriptional co-activators
YAP and TAZ. Oncotarget. 6:8676–8686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pratama MY, Pascut D, Massi MN and
Tiribelli C: The role of microRNA in the resistance to treatment of
hepatocellular carcinoma. Ann Transl Med. 7:5772019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perra A, Kowalik MA, Ghiso E,
Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore
E, Roncalli M, Giordano S and Columbano A: YAP activation is an
early event and a potential therapeutic target in liver cancer
development. J Hepatol. 61:1088–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Wang J, Zhang Y, Zhang Y, Ma L, Weng
W, Qiao Y, Xiao W, Wang H, Yu W, et al: MEK1 promotes YAP and their
interaction is critical for tumorigenesis in liver cancer. FEBS
Lett. 587:3921–3927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao Y, Khanal P, Savage P, She YM, Cyr TD
and Yang X: YAP-induced resistance of cancer cells to antitubulin
drugs is modulated by a Hippo-independent pathway. Cancer Res.
74:4493–4503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xia Y, Zhang YL, Yu C, Chang T and Fan HY:
YAP/TEAD co-activator regulated pluripotency and chemoresistance in
ovarian cancer initiated cells. PLoS One. 9:e1095752014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao Y and Yang X: The Hippo pathway in
chemotherapeutic drug resistance. Int J Cancer. 137:2767–2773.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huo X, Zhang Q, Liu AM, Tang C, Gong Y,
Bian J, Luk JM, Xu Z and Chen J: Overexpression of Yes-associated
protein confers doxorubicin resistance in hepatocellullar
carcinoma. Oncol Rep. 29:840–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang
LL, Gai RH, Zhu DF, Yang B, Zhu H and He QJ: Nuclear translocation
and activation of YAP by hypoxia contributes to the chemoresistance
of SN38 in hepatocellular carcinoma cells. Oncotarget. 7:6933–6947.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taniguchi K, Moroishi T, de Jong PR,
Krawczyk M, Grebbin BM, Luo H, Xu RH, Golob-Schwarzl N, Schweiger
C, Wang K, et al: YAP-IL-6ST autoregulatory loop activated on APC
loss controls colonic tumorigenesis. Proc Natl Acad Sci USA.
114:1643–1648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou TY, Zhou YL, Qian MJ, Fang YZ, Ye S,
Xin WX, Yang XC and Wu HH: Interleukin-6 induced by YAP in
hepatocellular carcinoma cells recruits tumor-associated
macrophages. J Pharmacol Sci. 138:89–95. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Song T, Zhou S and Kong X: YAP
promotes the malignancy of endometrial cancer cells via regulation
of IL-6 and IL-11. Mol Med. 25:322019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hiemer SE, Szymaniak AD and Varelas X: The
transcriptional regulators TAZ and YAP direct transforming growth
factor β-induced tumorigenic phenotypes in breast cancer cells. J
Biol Chem. 289:13461–13474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang L, Lee W, Oh JY, Cui YR, Ryu B and
Jeon YJ: Protective effect of sulfated polysaccharides from
celluclast-assisted extract of Hizikia fusiforme against
ultraviolet B-induced skin damage by regulating NF-κB, AP-1, and
MAPKs signaling pathways in vitro in human dermal fibroblasts. Mar
Drugs. 16:2392018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou N, Qu Y, Xu C and Tang Y:
Upregulation of microRNA-375 increases the cisplatin-sensitivity of
human gastric cancer cells by regulating ERBB2. Exp Ther Med.
11:625–630. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hao J, Lou Q, Wei Q, Mei S, Li L, Wu G, Mi
QS, Mei C and Dong Z: MicroRNA-375 is induced in cisplatin
nephrotoxicity to repress hepatocyte nuclear factor 1-β. J Biol
Chem. 292:4571–4582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chang Y, Yan W, He X, Zhang L, Li C, Huang
H, Nace G, Geller DA, Lin J and Tsung A: miR-375 inhibits autophagy
and reduces viability of hepatocellular carcinoma cells under
hypoxic conditions. Gastroenterology. 143:177–187.e8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nishikawa E, Osada H, Okazaki Y, Arima C,
Tomida S, Tatematsu Y, Taguchi A, Shimada Y, Yanagisawa K, Yatabe
Y, et al: miR-375 is activated by ASH1 and inhibits YAP1 in a
lineage-dependent manner in lung cancer. Cancer Res. 71:6165–6173.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang ZW, Men T, Feng RC, Li YC, Zhou D
and Teng CB: miR-375 inhibits proliferation of mouse pancreatic
progenitor cells by targeting YAP1. Cell Physiol Biochem.
32:1808–1817. 2013. View Article : Google Scholar : PubMed/NCBI
|
